UCB SA (OTCMKTS:UCBJF) Given Consensus Rating of “Moderate Buy” by Analysts

UCB SA (OTCMKTS:UCBJF) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company.

Separately, Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday.

UCB Trading Down 2.3%

Shares of OTCMKTS UCBJF opened at $277.44 on Wednesday. The company has a 50 day simple moving average of $292.79 and a two-hundred day simple moving average of $300.88. UCB has a fifty-two week low of $200.21 and a fifty-two week high of $345.39. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.